Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
07 März 2024 - 8:00AM
Highlights to be presented at Novo Nordisk’s Capital Markets Day
2024
Bagsværd, Denmark, 7 March 2024 – Novo Nordisk
is today hosting a Capital Markets Day (CMD) where the company is
providing a progress update on its Strategic Aspirations 2025.
The day will be centred around the Strategic Aspirations. During
the day, senior management presentations will cover corporate
strategy and purpose & sustainability (ESG), Research and early
development, Product Supply as well research and development
pipeline and performance within Diabetes care, Obesity care and
Rare disease. In addition, Novo Nordisk’s approach to
Cardiovascular & emerging therapy areas and financials are
presented.
The CMD will include break-out sessions covering Region EMEA,
Region China and Data science & Artificial intelligence.
Key highlights of the day are:
- Focus on early-stage pipeline
expansion by building on core research capabilities and new
technology platforms. Phase 1 data for amycretin, a novel GLP-1 and
amylin co-agonist, will also be presented
- Update on scaling of manufacturing
capacity and plans to increase patient reach
- Continued growth potential for
GLP-1-based semaglutide treatments within Diabetes care and
presentation of data from the kidney outcomes trial FLOW
- Update on commercial launches for
Wegovy® in the US and International Operations, an update of the
obesity research and development pipeline, including additional
data from the cardiovascular outcomes trial SELECT and overlap of
comorbidities in people with cardiometabolic diseases
- Update on the expanding pipeline
within cardiovascular disease
- Expected margin development in the
coming years
All sessions of the CMD are webcast live, and a replay will be
made available in the investor section of novonordisk.com.
Presentation material from the CMD will also be available
throughout the day in the investor section of novonordisk.com.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024